A note about the cover artist:

This picture is one of many stunning pieces of art from the collection of Rachel Gilbert. Rachel is a 21-year-old GIST patient from the United Kingdom. She has been living with GIST for almost seven years. She uses her art to channel beauty into the world to cope with her disease.
Dear Friends,

Since last year’s annual report much has happened. The Life Raft Group (LRG) continues to grow in size and complexity to match the needs of today’s GIST (Gastrointestinal Stromal Tumor) patient. Our program priority areas remain the same: Research, Information and Support, Patient Outreach and Assistance and Advocacy. However, in 2007, we expanded our capacity through innovative technologies and approaches to reach the evolving GIST community.

From a birds-eye view the Life Raft Group is a thriving young organization, its message reaching hundreds of thousands each year to help GIST patients and their loved ones in as many ways as possible. Here on the ground, the LRG is running a race against time, a relentless pursuit of survival. Faced with increasing cases of resistance to first-line treatment, the LRG continues its commitment to finding a cure through its work and funding the Resistance Research Project.

GIST is a rare cancer, but the struggle of cancer survivors is not uncommon in our world today. We will continue, with the help of our supporters, medical professionals and volunteers, to ensure that no one has to face GIST alone.

Stan Bunn
President

Norman J. Scherzer
Executive Director
To accomplish its mission, the Life Raft Group devotes its efforts to four major priority areas: Research, Advocacy, Information & Support, and GIST Outreach.

Research

In 2006, the Life Raft Group (LRG) set forth with a strategic plan and a team of expert researchers on the pathway to the cure. What is unique about this? The LRG not only funds this research but manages and facilitates communications of eight of the world’s leading GIST researchers from six different institutions. Our innovative grant system dramatically reduces administrative costs, holds each researcher responsible for specific results and redirects funding when necessary.

This year marked the one year milestone for the LRG Resistance Research Project and although the cure is not yet in hand we are optimistic that it will soon be in sight. In 2008, we plan to obtain more funding for this project and expand the team to include other expert researchers. (Please see Fletcher’s report for more details.)

LRG GIST Patient Registry

The LRG maintains a unique patient registry, tracking patients’ medical status to allow us to provide information to GIST patients and caregivers. Timely knowledge and information are key to survival.

All of our information comes directly from patients and caregivers. Using this data, we examine questions that are not being answered quickly enough by current trials or not being examined at all. We monitor the latest treatments for early indications of a response. We look for treatment and response trends that can help our members reach tomorrow’s cure.

Since the LRG is not limited by the design of traditional clinical trials, we have significantly increased flexibility over areas that we can examine. We are better able to follow patients over long periods of time and across institutional boundaries. Because the LRG was founded by patients and caregiv-
ers, we are in touch with the real life issues that come up on a daily basis. This connection allows us to track treatments and issues that are of concern to GIST patients today. In 2007, the LRG updated the 2004 Gleevec dosage study and revealed, for the first time, that patients on a higher dose of imatinib had significantly higher overall survival rates.

By fully embracing the role of patient advocate, we have now become patient scientists changing the medical research environment.

**Treatment and Surveillance**

With a growing number of GIST patients looking for the next step in their treatment, we have strengthened our focus on rigorously tracking clinical trials and publishing monthly updates in the newsletter. The unique molecular targets for each trial are also listed so that patients are not repetitively trying similar drugs. The LRG continues to encourage patients to get mutational testing in order for their physicians to take advantage of that information when developing survival strategies.

Through our internal research, we also examine trends and preliminary reports so that patients can make informed decisions about the future of their care.

**Advocacy**

The LRG has become a formidable advocate for GIST patients. As we grow, so does our ability to help GIST patients. This year the LRG’s major efforts included the adoption of the Bad Nauheim Declaration, which aims to create a standard of care for all GIST patients in any healthcare system across the world so that all patients are treated equally. The LRG has also lobbied against the Medicare and Medicaid proposed restrictions limiting the use of drugs that treat anemia, a common side effect of most cancer medications. In addition to our public advocacy work, the most important efforts we carry out are done case by case for patients with nowhere else to turn. Many times patients or their loved ones contact the LRG for help from countries all over the world. They are facing obstacles that range from not receiving their prescriptions on time to outright refusal of treatment by their own government agencies. Often, patients are in dire need of treatment but, because of poor health, do not qualify for a clinical trial. The LRG works with those patients to gain access to a drug that will help them survive. The LRG goes above and
beyond most patient organizations by stepping in as the patients’ true advocate, using every method possible from persuasion to confrontation, to make sure that patients get needed treatment.

**Information & Support**

The LRG is committed to providing information and support to the GIST community including patients, their families, friends and medical professionals. With growing resistance to first-line treatment prompting the development of so many new drugs, it is of utmost importance for everyone to stay up-to-date.

This year the LRG focused on expanding our newsletter content; restructuring our website with new content and a focus on making it more user-friendly; and developing more education materials to address specific needs such as navigating clinical trials. The LRG also employed the use of webcasts as an educational tool. Webcasts allow attendees to go online and log on to important seminars such as “Living Well with Side Effects: A Guide to Side Effects Management”; “Mutational Testing: Broken Down”; “‘GIST’ the Basics“ and many more. Through innovative technology, we have reached thousands of people in their very own homes. Webcasts are also stored in our new video library which is easily accessible on the LRG website.

The LRG was born on the internet and continues to provide patient support through our private email community. This forum allows only GIST patients and caregivers to discuss sensitive topics and exchange ideas to support everyone’s quality of life.

**GIST Outreach**

In addition to the newsletter, webcasts, website and email community, the LRG fosters the development of local groups that meet in-person across the United States. This year alone we have added 11 new groups to our ever-growing list. We also work with international chapters and sister groups through the Global GIST Network which is funded by the LRG. This year we have added patient liaisons in Belgium, Lithuania, Thailand and Uruguay. These volunteers serve vital roles to help GIST patients with treatment issues specific to their countries. With the help of many outstanding volunteers distributing educational materials, hosting events and launching personal campaigns, we are able to cast a wider net to create awareness for this rare cancer.

We began working on pharmacy outreach this year hoping to reach all those patients who are on prescription drugs that treat GIST. So far, we have developed a pilot collaboration with a national pharmacy chain which has disseminated information about GIST to all of their locations.
The LRG Resistance Research Progress Report

GIST THERAPY RESISTANCE MECHANISMS
YEAR 2 PROGRESS REPORT:

Research to identify therapeutic methods that operate in synergy with Gleevec (imatinib) in achieving long-term remission and cure of GIST

In the past year, LRG research funding has enabled progress in identifying novel treatment strategies for GIST. Despite the remarkable clinical responses to KIT and PDGFRA kinase inhibition, GIST clinical progression can occur even in individuals with spectacular initial response to imatinib. For this reason, LRG is committed to funding research programs to develop synergistic targeted therapies that counteract imatinib-resistance in GIST. In the past year, research progress was made by studying new treatment methods in GIST surgical specimens, GIST cell lines, and mouse models of GIST. The urgent aims in all these studies are to identify therapies that function synergistically with imatinib in destroying GIST cells.

Each of the funded scientists performs GIST research that is coordinated with the efforts of the other scientists in this LRG program. Great pains have been taken to enable collaboration while eliminating redundant research efforts, such that team achievements are emphasized. This rigorous approach will continue to maximize the LRG research productivity, and – specifically – identify treatment approaches that synergize with imatinib and other KIT kinase inhibitors in enabling a higher cure rate for patients with GIST.

It is hoped that additional research priorities can be supported during the next several years of LRG funding. In particular, there is urgent need for therapies that operate in synergy with imatinib by increasing GIST cell apoptosis. The LRG resistance effort would be well-served by encouraging more studies of GIST survival and apoptosis mechanisms.

The imatinib-resistance studies described here are essential to therapeutic progress in GIST. These studies will likely reveal that combinations of GIST therapies are needed to consolidate initial remissions, forestall the emergence of clinical resistance, and lead to increased cure rates. At present, the LRG research program funds ten “priority” projects. Each of these projects has substantial, near-term potential for enabling development of novel GIST therapies. The Year 2 progress for each of these highest-priority projects is summarized below.

Oncogenic signaling mechanisms as novel therapeutic targets: These studies continue to highlight the crucial role of the PI3-K kinase protein in transmitting KIT and PDGFRA oncogenic signals in GIST cells. Specifically, the LRG research group have shown that a subtype of PI3-K, known as “catalytic alpha” is most relevant in GIST, and future studies will prioritize validations of new drugs that inhibit this particular PI3-K subtype. The LRG studies have also demonstrated several proteins that bind to KIT in GIST cells: one example is the protein kinase C theta protein, which in the next year will be evaluated as a novel therapeutic target in GIST.

Wildtype GIST: This project was suspended last year, because there were insufficient numbers of cases identified in the early months of the research program. Fortunately, substantial progress has been made in the past year, such that KIT/PDGFRA wildtype GISTs, as identified by mutational analyses of paraffin sections, can be used to identify the biologic mechanisms responsible for KIT activation in these cases. The recent work has identified several kinases, beyond KIT or PDGFRA, that are found at high levels in the wildtype GISTs, and that might serve as additional therapeutic targets.

Primary Resistance: Some GISTs are caused by KIT or PDGFRA mutations that do not respond well to imatinib. Research progress in the past year has highlighted that alternate therapies, including sunitinib, sorafenib, and nilotinib can be
effective against subsets of these imatinib-resistant primary mutations. In addition, some KIT kinase inhibitors have greater potency than imatinib against nonmutant KIT, and these inhibitors may be particularly effective against KIT/PDGFRA wildtype GISTs.

**Stable disease after imatinib:** Stable disease, i.e. GIST cells that are suppressed but not killed by imatinib, remains a major problem for most people with inoperable GIST. The recent LRG-funded studies show that a variety of imatinib-resistance mutations can be found at low levels in such stable GIST cells, accounting for partial resistance to therapy. However, other cells persist in absence of such resistance mutations, and new therapies – particularly those which are highly effective in inducing GIST cell apoptosis – are needed, in conjunction with KIT kinase inhibitor drugs, to destroy those cells. Future studies will focus on identifying drugs for stable GIST, and developing highly sensitive assays that can detect treatment-resistance mutations in blood samples.

**Secondary resistance mechanisms:** Continued progress has been made in identifying drugs that can inhibit secondary imatinib-resistant mutations. In addition, novel and extremely sensitive assays have been developed to detect low-levels of imatinib (and other KIT kinase inhibitor) resistance mutations in GIST biopsy materials.

**Kit Degradation:** These studies have identified small molecule HSP90 inhibitors that are exceptionally effective against the KIT oncoproteins in GIST cells. Preliminary studies show that greater efficacy, particularly in mouse GIST assays, is obtained with the combination of HSP90 inhibitor and imatinib, compared to using either drug on its own. Future studies will further evaluate these treatment synergies, and will determine mechanisms of HSP90 inhibitor resistance in GIST.

**Murine Models:** The laboratories of Drs. Besmer and Rubin have continued to develop mice that develop GIST and are therefore useful in testing new GIST drugs. Additional progress has included development of mice with imatinib-resistant GISTs, which will provide a system to test drugs of potential benefit for individuals whose GISTs have progressed while receiving imatinib.

**Resource Development (imatinib sensitive & resistant):** Exceptional continued progress has been made in developing new immortal GIST cell lines and mouse xenografts, which are indispensable for testing GIST drugs. The LRG scientists have shown that these resources provide biologically faithful model of GISTs in humans, and as such are highly useful in screening studies to identify new GIST drugs. Additional cell lines have been developed that permit drug testing against the wide variety of KIT and PDGFRA mutations found in GIST. These collective resources are, without doubt, one of the great strengths of the LRG research consortium.

**Pediatric GIST:** Dr. Antonescu’s research group has continued to shed light on the biological differences between pediatric and adult GISTs. Studies in the past year have shown that the frequency of genetic syndromes, particularly the so-called “Carney’s Triad”, may be underestimated in children with GIST. A small subset of pediatric GISTs have biologic similarities with adult GISTs, and these tumors can be expected to respond better than others to imatinib. However, most pediatric GISTs have substantial biologic differences from adult GISTs, including a lack of KIT mutations. Activated KIT is nonetheless important in these KIT/PDGFRA-wildtype tumors, and lab studies suggest that newer-generation KIT kinase inhibitors, such as nilotinib, might be therapeutically useful in these pediatric wildtype GISTs.

**Tissue Banks:** The LRG central repository for frozen and paraffin-embedded GISTs supports the collective research efforts in this program. These specimens are studied to identify novel oncogenic mechanisms in KIT/PDGFRA-wildtype GISTs, and to identify additional therapeutic targets in GISTs with KIT or PDGFRA mutations.
**LIFE RAFT BOARD**

Stan Bunn, President  
Jerry Cudzil, Secretary-Treasurer  
John Poss, Fundraising Co-chair  
Robert Book

Mia Byrne  
Chris Carley  
Jim Hughes  
Jerry Knapp, Fundraising Co-chair

Dr. Arnold Kwart  
Ray Montague  
Rodrigo Salas  
Silvia Steinhilber

**VOLUNTEERS**

General Counsel:  
Thomas Overley  
Accountant:  
Kristi Rosenberg  
Accounting Firm:  
Mackey & Mackey  
Database Consultant:  
Steven Rigg  
List Manager:

Mia Byrne  
Newsletter Editor Emeritus:  
Richard Palmer  
Web Designer:  
Joe Trzepla  
Fundraising co-chairs:  
John Poss & Gerald Knapp  
Science Team Member:  
Jim Hughes

Science Team Member:  
David Josephy  
Science Team Member:  
Michael Josephy  
Science Team Member:  
Rick Ware  
Science Team Member:  
Glenn Wishon

**GIST REPRESENTATIVES**

**STATE:**  
Alabama: Pat George  
Arizona: Linda Martinez  
Colorado: Jerry Call  
California: Floyd Pothoven, Martha Zielinski  
Florida: Skip Ryan  
Georgia: Pat Lemeshka  
Idaho: Janet Conley

Illinois: Richard Kinzig  
Indiana: Robert Book  
Kansas: Jim Toyne  
Maryland: Bonnie Emerson  
Massachusetts: Janice Leary  
Michigan: Ellen Rosenthal  
Missouri: Bob Tikkanen  
Nevada: Erik Krauch  
New Jersey: Anita Getler

New York: Dan Cunningham  
North Carolina: Chuck Korte  
Ohio: Kaye Thompson  
Oregon: Gail Mansfield  
Pennsylvania: Kim Trout  
South Carolina: Al Boyle  
Tennessee: Alice Sulkowski  
Texas: Kerry Hammett  
Washington: Deanne Snodgrass

**COUNTRY:**  
Australia: Katharine Kimball  
Belgium: Kris Heyman  
Bolivia: Virginia Ossio  
Brazil: Alexandre Sakano  
Canada: David Josephy  
China: Ruijia Mu  
Colombia: Jaime Peralta  
Costa Rica: Michael Josephy  
France: Estelle LeCointe  
Germany: Markus Wartenberg

Iran: Negar Amirfarhad  
Ireland: Carol Jones  
Israel: Ben Shtang  
Italy: Anna Costato  
Kenya: Francis Kariuki  
Lithuania: Virginija Zukauskiene  
Malaysia: Yong Choo Sian  
Mexico: Rodrigo Salas  
Netherlands: Contactgroep GIST

Norway: Jan Einar Moe  
Poland: Stan Kulisz  
Romania: Simona Ene  
Russia: Tanya Soldak  
Singapore: Yong Choo Sian  
Switzerland: Ulrich Schnorf  
Thailand: Kittikhun Pompakakul  
Turkey: Haver Tanbay  
U.K.: David Cook
The Life Raft Group would like to express its deepest thanks to the donors whose generous support and partnership make our work possible. We are grateful for the following contributions and grants received for 2007. To see who some of these donations honored please go to www.liferaftgroup.org

**$100,000 & Above**
Novartis Pharmaceuticals Corp.
Pfizer Inc.

**$20,000 - $99,999**
Stan Bunn
Jerry Knapp
Rodrigo Salas
Anonymous

**$10,000 - $19,999**
Carlos & Liana Baldor
Chris Carley
Jerry Cudzil
Jim Hughes
Arnold Kwart MD
Amgen
Citigroup
The Arbor Foundation

**$5,000 - $9,999**
Chris Carley
David & Maxine Clark
Dale Couch
Maurice Lipnick
David Smith & Patricia Brady
TXL Mortgage Corp. Poss
Marietta & James Robinson

**$1,000 - $4,999**
Dorothy Battles
LP Houston Beazer Homes Texas
Isadore Bergner
Robert Book
Kathryn Byrne
Roger & Lucy Carter
Karl Cerny
Wokie Onike David
Margaret Z. Deutsch
David M Falk
Thomas C. Green
Dolores Hawkins
Julian Haydon
Nobie Haynie
Philip & Lee Hixon
Douglas Horst
Peter Kavaloski
Austin Kiplinger
Jacky Lewkovich
Eddie Martin
Michael Miller
Gary Noble
Henry & Bobbie Offen
Joe Partain
Jeff Payson
Nicole Polston
Lester Poretsky
Fernando Prudencio
Patrick Raynal
Doris S. Rosenthal
Richard Sharlin
Gerald Stern
Terin Vivian
Kurt Watzek
Randall S. Welsh
Robert & Wanda Wigand
Silvia Williams-Steinhalber
Cervelle Homes
Brosche Family Foundation
Congressional Bank
Fox Goldberg Foundation Inc.
Gradison Foundation
Gulf & Basco L.P.
Hallmark Design Homes LP
Keryx Biopharmaceuticals,Inc.
Koteen Foundation
Marion & Robert Rosenthal Foundation
Triangle Community Foundation
The Olender Foundation
Washington Brain & Spine Institute
Brosche Family Foundation
Trulcan
J.Lefcourt Philanthropic Fund
Texas State Bank
Dublin's Pub
Tilson Home Corp.
Quintiles Transnational Corp.

**$500 - $999**
David Allentuck
Joe Aranda
John & Nancy Barclay
Bruce Barclay
Marilyn Berman Pollans MD
Ann Brennan
John R. Brimsek
Terry H. Brooks
Georgia Caraway
LLC CCM
Purnell & Joan Choppin
Marshall L. Cole
Anne E. Corbeille
Robert Crowley
Doris Dallow
Jack Dimaio Jr.
Stanley Drab
Cyril & Risa Drabinsky
Scott Dudley
Daniel & Jane Duhl
Peter & Julianne Durant
Billie Ellis
Richard & Lois England
Noah Estrin
Chris Flammia
Lady Galin
Stephen D Gardner
Kenneth R. Gilman
Barry & Palmer Graham
Sylvia Greenberg
Leo Halpert
Doris & Sherry Jeffery
Fritz R. Kahn
Dennis & Mary Kane
Richard J. Kinzig
Dr. & Mrs.Marvin Korengold
George Kourpias
Patricia G. Lewis
Winifred Lynn
Alan Madian
Clinton Matter
Valerie Matthews
Glenn Miller
Laurence H. Miller MD
Jonathan Nash
Lori Nash
Steve Norwood
Sergui & Eleonora Novikov
John Ramsey
Steve & Darlene Rigg

Jerry Cudzil’s and John Poss’s Poker Tournaments raised over $100,000 in 2007!

Castlerock Communities LP
ABI Brooklyn Homes
Dakota Blue Homes
Deerwood Homes
Lane Family Foundation
IIC. B.L.P.
Mr Smith's of Georgetown
Nuway Homes Texas
Rappaport Management Co.
Ratner Family Foundation
Seven Oaks Foundation
TXL Mortgage Corp.
Wallen Associates
The Babble Ball
Purcells Cove Social Club

**$250 - $499**
Betty & Roy Anderson

---

David Smith and Pat Brady donate stock each year in memory of their good friends’ Jim and Marge Hughes’ daughter, Nancy Hughes Welsh (right).
$250 - $499 (cont.)
Joan Angerer
Glen & Elizabeth Banks
Jose Luis Berrios
Jose Berrios
Simon S. Chung
Elizabeth Colice
Jenny & Janet Conley
Jack Dimiao, Jr.
Ann P. DiMisa
Robert A. Dooling
Alexander Doudoumopoulos
Robert L. Earl
Robert & Jeannie Greene
Maya Grinchenko
Albert & Linda Hinton
Reinhardt Jesse
Russell & Cindy Kaye
Diana Kearney
Lawrence Kraus
Leo A. Legatski
Sidney A. Levy
Jerome P. Lewis
Robert Lipnick MD
Eilish Loughran
Lai Oy Louie
John W Maass
George McInnis
Daniel K. Meyers
Markku & Birgit Miettinen
Marc & Beth Mintz
Ruijia Mu
Stephen Nechtw
Abbas Patni
Seymour Perl MD
Donald & Rosine Perlman
Deborah Reinhart
Semyon & Rimma Reznik
Patricia Ricard
Gloria Richmond
Paula Roach Vettel MD
Kenneth Samet
Michele Scheiperpeter
Diane Schmitz
James & Pamela Seymour
William & Ellen Shaw
Jacque Sierad
Harold Silver
Horard Silverberg
Richard Sorg
Henry & Sharon Starr
Mary Stowell
Richard N. Tager
Guy Thomas
Grant Thomas
Harold & Suzanne Tober
Puppy Villarreal
Stig Von Post
Marc Wasserman
Richard & Toni White
Peggy & David Wicker
Robert Wilkinson
Roselina Wong-Parlove
Hans Wyss
Andrew Young
Joseph & Anna Zappala
Anonymous
Key Pharmacy & Home Health Care
Posner-Wallace Foundation
Washington Healthbeat

$100 - $249
Leonard I. Abel
Morton Abramowitz
Richard E. Abrams
Florence Allentuck
Anthony John Aloj
Melvin G. Alper MD
Harvey & Cora Alter
Phillip Archunde
Brian J. Arling MD
Michael Arons
Lydia Atkinson
Gregory Auger
Morton Bahr
Connie Baney
Burton & Amelie Bank
Sandi & Michael Banks
Sandra S. Baraff
Frank & Heather Barbara
Lawrence Baskir
James Bass
Harold & Gloria Baston
Howard Bayewitz
Jacqueline Becker
Grace Bedoya
Richard Bellofatto
Paula & Barry Belman
Betty Benjamin
Paul & Joanne Benoit
Louis & Joan Berge
Joan Berkowitz
Ugo & Carla Bertocci
John Bigelow
Caryn & Ron Blittker
Stuart Marshall Bloch
Leah Blum
Marjorie Bobholz
George & Stephanie Bogue
Fred & Laura Bond
Monica Bonifaz
Stuart Bonwit
Andrew & Lisa Boschma
Emily Bowden
Margaret Bowman
Angela Boyter
Nancy Brock
Gerald Brody
Pierre & Virginia Brousseau
Kara Brown
Barbara & John Buch
Daniel J. Buck
Evangelos A. Calamitsis
Sue & Richard Camann
Albert J. Carnut
Gail Canning
Luis Carliaga
Pety Carliaga
Christopher Cartzendarfner
Stuart M. Cherntob
Harvey Cherner
Boris E. Cherney
Giordano Chiaruttini
Leonard & Phyllis Chorazy
Thomas B. Christensen
Eleanor & Donald Clark
John N.Jr. Clark
Michael F. Clayton
Chuck Clupper
Lara D. Coggin
David Cohen
Marshall M. Cohen
George F. Cole
Tom Colwell
Jose Luis & Cecilia Contreras
John J. Cooney
Evelyn Horn Courtin
Jack & Evelyn Courtin
Susan K. Cowart
Maureen Cummins
H.Greig Cummings Jr.
Albert W. Currier
Howard & Arlene Danziger
Maria C. Davidson
Anita Dekelbaum
Frank & Karyn Deparjis
Frank DeParis
Pierre DeRaet
Antionette Desykas
James H. Derrington
Ann Dixon
George Downes
Charleen & William Duke
Elbert Duncan
Marsha & Charles Dunn
Donald & Jenny Dunner
Peter Durant
Christine Echer
Patricia Ehresmann
Daniel & Marina Ein
Ken & Judie Elder
Jeff & Pam Emerson
Stephanie Emerson
Eleanor Falkenstern
Jessie & George Falkenstern
Betty Fatzie
Cary Mark Feldman
Miriam R. Feldman
Joan Fitzgerald
Nancy Fletcher
Harold A. Forman
Glen Foster
Lucia & George Foster
Richard K. Fox
Glenn & Beth Franz
William G. Frederick
Robert Fried
Johathon & Lynn Friendly
Sue Galler
Enrique Garcia
Beatriz Garcia
Alyse Gart
Frederick Geiger
Jay & Ruth Gerber
Joseph M. Giordano
Jeffrey M. Gitelman
Seymour Glianz
Robert & Sandra Glassman
Simun Glavinic
Peter F. Gold
Leonard & Roberta Goldstein
Richard Gordy
Edward Grant
Donald R. Greeley
Howard T. Greeley
Michael Green

Team Viva Carolina ran the Long Beach Marathon and raised over $10,000 in honor of Carolina Ponce Williams
<table>
<thead>
<tr>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thomas M. Keyes</td>
</tr>
<tr>
<td>Mildred Kinzig</td>
</tr>
<tr>
<td>Donald Kirk</td>
</tr>
<tr>
<td>Jean E Kirnan</td>
</tr>
<tr>
<td>John J Klein</td>
</tr>
<tr>
<td>Chuck &amp; Peggy Korte</td>
</tr>
<tr>
<td>Lee LaBorwit</td>
</tr>
<tr>
<td>Bruce S. Lane</td>
</tr>
<tr>
<td>Diana &amp; John Lanza</td>
</tr>
<tr>
<td>Ira Laster Jr.</td>
</tr>
<tr>
<td>Lawrence J Latto</td>
</tr>
<tr>
<td>Arthur, Lazarus Jr.</td>
</tr>
<tr>
<td>J. Martin Lebowitz</td>
</tr>
<tr>
<td>David Levene</td>
</tr>
<tr>
<td>B. Levin</td>
</tr>
<tr>
<td>John A. Leyes</td>
</tr>
<tr>
<td>Judith F Lifton</td>
</tr>
<tr>
<td>Diane M. Linden</td>
</tr>
<tr>
<td>Clare Lindquist</td>
</tr>
<tr>
<td>Donor &amp; Linda Lion</td>
</tr>
<tr>
<td>Alexander J. Lipske Jr.</td>
</tr>
<tr>
<td>Linda Lipson</td>
</tr>
<tr>
<td>Paul Liston</td>
</tr>
<tr>
<td>Joshua Lonsk</td>
</tr>
<tr>
<td>Donald Lubick</td>
</tr>
<tr>
<td>Janet Machuca</td>
</tr>
<tr>
<td>Seth Mankin</td>
</tr>
<tr>
<td>Halford Manningre</td>
</tr>
<tr>
<td>Timothy &amp; Gail Mansfield</td>
</tr>
<tr>
<td>Hector Marin</td>
</tr>
<tr>
<td>FrankA Marino</td>
</tr>
<tr>
<td>Stanley C. Marinoff</td>
</tr>
<tr>
<td>Carolyn Markowitz</td>
</tr>
<tr>
<td>William L. Marre</td>
</tr>
<tr>
<td>Paul J. Mason</td>
</tr>
<tr>
<td>John G. McDavid</td>
</tr>
<tr>
<td>Martin J. McDonnell</td>
</tr>
<tr>
<td>Rose McKnight</td>
</tr>
<tr>
<td>Col Efrain &amp; Judy Medina</td>
</tr>
<tr>
<td>Robert Melillo</td>
</tr>
<tr>
<td>Sander &amp; Irene Mendelson</td>
</tr>
<tr>
<td>Anne M. Menotti</td>
</tr>
<tr>
<td>Sharon J. Metro</td>
</tr>
<tr>
<td>Sheila M. Meyer</td>
</tr>
<tr>
<td>Sheldon Meyers</td>
</tr>
<tr>
<td>Frank Midgley MD</td>
</tr>
<tr>
<td>Devon Lee Miller</td>
</tr>
<tr>
<td>Jeff &amp; Robyn Miller</td>
</tr>
<tr>
<td>Kari &amp; Harry Miller</td>
</tr>
<tr>
<td>James Mills</td>
</tr>
<tr>
<td>Jack Minker</td>
</tr>
<tr>
<td>Timothy G Mischo</td>
</tr>
<tr>
<td>Louise Mochel</td>
</tr>
<tr>
<td>Jan-Einar Moe</td>
</tr>
<tr>
<td>Howard Monderer</td>
</tr>
<tr>
<td>Marilyn Montuori</td>
</tr>
<tr>
<td>Salvatore Montuori</td>
</tr>
<tr>
<td>Chad &amp; Kira Montuori</td>
</tr>
<tr>
<td>Mary Fee Morrison</td>
</tr>
<tr>
<td>Tamara K. Mundy</td>
</tr>
<tr>
<td>Seishin Murahashi</td>
</tr>
<tr>
<td>Joseph S. Musher</td>
</tr>
<tr>
<td>Beverly Nerenberg</td>
</tr>
<tr>
<td>Howard &amp; Deborah Nussbaum</td>
</tr>
<tr>
<td>John &amp; Janice O'Brien</td>
</tr>
<tr>
<td>Daniel F O'Keefe</td>
</tr>
<tr>
<td>Donald &amp; Jane O'Keffe</td>
</tr>
<tr>
<td>Vandoorn Ooms</td>
</tr>
<tr>
<td>Roberta H. Ostar</td>
</tr>
<tr>
<td>Donald K Palmer</td>
</tr>
<tr>
<td>J.Hardy Patten</td>
</tr>
<tr>
<td>Tina Paulsen</td>
</tr>
<tr>
<td>Paz Paz</td>
</tr>
<tr>
<td>Susan Pedersen</td>
</tr>
<tr>
<td>James Pegram</td>
</tr>
<tr>
<td>Rosemary Perkins</td>
</tr>
<tr>
<td>Theodore Peyer</td>
</tr>
<tr>
<td>Joe Pfeifer</td>
</tr>
<tr>
<td>Thomas J. Phillips</td>
</tr>
<tr>
<td>Michael Phillips MD</td>
</tr>
<tr>
<td>Jennifer Pierce</td>
</tr>
<tr>
<td>Jonathan &amp; Joan Pincus</td>
</tr>
<tr>
<td>Pam Pollard</td>
</tr>
<tr>
<td>Diego Ponce</td>
</tr>
<tr>
<td>Ian &amp; Judy Portnoy</td>
</tr>
<tr>
<td>Stephen &amp; Barbara Powers</td>
</tr>
<tr>
<td>George Preisinger</td>
</tr>
<tr>
<td>Rose &amp; Richard Pridgen</td>
</tr>
<tr>
<td>Dennis Priebat</td>
</tr>
<tr>
<td>Linda Puryear</td>
</tr>
<tr>
<td>M.L. Raphael</td>
</tr>
<tr>
<td>Alan Rapoport</td>
</tr>
<tr>
<td>Andrea &amp; Tob Mailler Ready</td>
</tr>
<tr>
<td>Stanley S. Reines</td>
</tr>
<tr>
<td>Francis &amp; Margaret Richetti</td>
</tr>
<tr>
<td>Nancy Ridgway</td>
</tr>
<tr>
<td>Cheri Rizer</td>
</tr>
<tr>
<td>Charles Roberts</td>
</tr>
<tr>
<td>William A. Roberts III</td>
</tr>
<tr>
<td>Gary R. Rottmann</td>
</tr>
<tr>
<td>Jim &amp; Alice Rudd</td>
</tr>
<tr>
<td>Douglas Ryan</td>
</tr>
<tr>
<td>Elaine Rys</td>
</tr>
<tr>
<td>Edwin Saa</td>
</tr>
<tr>
<td>Howard M. Sachar</td>
</tr>
<tr>
<td>Emanuel Sadwin</td>
</tr>
<tr>
<td>Robert Saks</td>
</tr>
<tr>
<td>Nestor &amp; Beth Sanchez</td>
</tr>
<tr>
<td>Familia Sagredo Sanchez</td>
</tr>
<tr>
<td>Ethel Schafer</td>
</tr>
<tr>
<td>W.Thomas Scheiber</td>
</tr>
<tr>
<td>Shirley Scher Jacobs</td>
</tr>
<tr>
<td>Carol Schlesinger</td>
</tr>
<tr>
<td>Harold M. Schoolman</td>
</tr>
<tr>
<td>Gayle &amp; Scott Schulman</td>
</tr>
<tr>
<td>Charles Schwartz</td>
</tr>
<tr>
<td>C.Delores Scott</td>
</tr>
<tr>
<td>May Ruth Seidel</td>
</tr>
<tr>
<td>Stuart F. Seides MD</td>
</tr>
<tr>
<td>Allegra Sensenig</td>
</tr>
<tr>
<td>Larry B. Shagle</td>
</tr>
<tr>
<td>Kenneth Shapiro</td>
</tr>
<tr>
<td>Mervin &amp; Ruby Shello</td>
</tr>
<tr>
<td>William Sherman</td>
</tr>
<tr>
<td>Victor &amp; Rhoda Shields</td>
</tr>
<tr>
<td>Anne Shuman</td>
</tr>
<tr>
<td>Victor &amp; Beatrice Siegel</td>
</tr>
<tr>
<td>Norma &amp; Robert Siegel</td>
</tr>
<tr>
<td>Karen Silverstein</td>
</tr>
<tr>
<td>Maria Singson</td>
</tr>
<tr>
<td>David G. Smith</td>
</tr>
<tr>
<td>Dwight O. Smith</td>
</tr>
<tr>
<td>Maria Smith</td>
</tr>
<tr>
<td>David Snider</td>
</tr>
<tr>
<td>Gerald &amp; Deanne Snodgrass</td>
</tr>
<tr>
<td>Katherine Somervell</td>
</tr>
<tr>
<td>Robert &amp; Frances Spar</td>
</tr>
<tr>
<td>Harald &amp; Karin Spruch</td>
</tr>
<tr>
<td>Gary R. Squires</td>
</tr>
<tr>
<td>Jeffry Stallsmith</td>
</tr>
<tr>
<td>Hugh Steinberger</td>
</tr>
<tr>
<td>Lawrence Steinman</td>
</tr>
<tr>
<td>Reuben Sternfeld</td>
</tr>
<tr>
<td>Margrete &amp; Michael Stevens</td>
</tr>
<tr>
<td>John Stinson</td>
</tr>
<tr>
<td>George W. Stockton Sr.</td>
</tr>
<tr>
<td>Christi Stone</td>
</tr>
<tr>
<td>Alan &amp; Jerlyn Stone</td>
</tr>
<tr>
<td>Harvey Stork</td>
</tr>
<tr>
<td>Murray Strasberg</td>
</tr>
<tr>
<td>Cynthia R. Sugimoto</td>
</tr>
<tr>
<td>Janice Summers</td>
</tr>
<tr>
<td>Gerald Summers</td>
</tr>
<tr>
<td>Alvin Tanenholz</td>
</tr>
<tr>
<td>John Tarantino</td>
</tr>
<tr>
<td>Valentin V. Tepordei</td>
</tr>
<tr>
<td>Linda A. Thompson</td>
</tr>
<tr>
<td>Antonio Tijman</td>
</tr>
<tr>
<td>Kittie Tomson</td>
</tr>
<tr>
<td>Patricia A. Tyson</td>
</tr>
<tr>
<td>Maria Vallin</td>
</tr>
<tr>
<td>Gustavo &amp; Maria Vazquez</td>
</tr>
<tr>
<td>Paula Vettel</td>
</tr>
<tr>
<td>James Vlogianitis</td>
</tr>
<tr>
<td>Leland J. Volker</td>
</tr>
<tr>
<td>Albert &amp; Doris Wahl</td>
</tr>
<tr>
<td>Rick &amp; Kathie Ware</td>
</tr>
<tr>
<td>Janice Watson</td>
</tr>
<tr>
<td>Carol Webb</td>
</tr>
<tr>
<td>Ruth Weigand</td>
</tr>
<tr>
<td>Susan Weigand-Smith</td>
</tr>
<tr>
<td>Steven J. Weiss</td>
</tr>
<tr>
<td>Stephen &amp; Madeline Weiss</td>
</tr>
<tr>
<td>Charles Welch III</td>
</tr>
<tr>
<td>Rachel B. Whitted</td>
</tr>
<tr>
<td>John W. Williams</td>
</tr>
<tr>
<td>April Wilson</td>
</tr>
<tr>
<td>Irene Wing</td>
</tr>
<tr>
<td>Victor &amp; Susan Winocur</td>
</tr>
<tr>
<td>Sandra Young</td>
</tr>
<tr>
<td>John Young III</td>
</tr>
<tr>
<td>Victor K Yu</td>
</tr>
<tr>
<td>Stella G. Zanoff</td>
</tr>
<tr>
<td>Heather Zdan</td>
</tr>
<tr>
<td>Mark Zdan</td>
</tr>
<tr>
<td>Robert Zich</td>
</tr>
<tr>
<td>Martha Zielinski</td>
</tr>
<tr>
<td>Holden Properties</td>
</tr>
<tr>
<td>CLK Construction</td>
</tr>
<tr>
<td>Digital Security</td>
</tr>
<tr>
<td>Hasco Industrial Supply</td>
</tr>
<tr>
<td>KLC Enterprises</td>
</tr>
<tr>
<td>Leasing Resources</td>
</tr>
<tr>
<td>LRM Realty</td>
</tr>
<tr>
<td>Merck Sharp &amp; Dohme FCU</td>
</tr>
<tr>
<td>Paragon FDU</td>
</tr>
<tr>
<td>Sobel Shipping</td>
</tr>
<tr>
<td>Retire Inc.</td>
</tr>
</tbody>
</table>
$100 - $249 (cont.)
Chicago Tribune Foundation
Jekl Gourmet Sandwiches
Quin Family Foundation
Anonymous

$50 - $99
Mark A. Abramson
Richard Ackerman
Alston Ahern
Virginia Anderson
John Angerer
William Angerer
Rita Archunde
Bryan & Nancy Balke
Frederic W. Bancroft
Maria Barber
Charles Barbera
Margaret Barton
Marvin A. Becker MD
Walt Benson
Marisol Bernal-Epstein
Irene Bhr Fritz
Dieter & Eileen Blobaum
David G. Borenstein
Richard C. Boys Jr.
Barbara Brandwein
Maria Barber
Frederic W. Bancroft
Bryan & Nancy Balke
Rita Archunde
William Angerer
Rita Archunde

Life Raft Staffers Elizabeth Braun, Erin Kristoff and Tricia McAteer threw a ball to celebrate Trish’s birthday and raised over $1,000 for the LRG’s Research!

Fred & Helen Emert
Allan & Ruth Falkenstein
Mar y & Edward Farley
Estelle R. Feit
Arlene Finger
Maria Antonia Fiorentino
Pau & Sharon Fisk
Sophia E. Fleischer
Cathy Forbes
George Forbes
Denise Foureire
Miriam Fox-Newton
Robert & Sylvia Frank
Robert E. Fuhr
Velma K. Gallblum
Elizabeth Gardner
Kimberly Gioviani
Robertta Goldwater
Mauro Gaglio
Mauricio Gumucio
Mauricio Gumucio
Marianne F. Guran
Henry & Kate Haas
George R. Hall
Amy Harlan
Thomas & Donna Harris
Elaine Hauptman
Kim R. Heinicka
Julie Heinicka
Jodie Heinicka
Janet & Hendrickson
Mary Kay Hertlein
Gerald Herz
Joan Hicks
Carola Hoelscher-Egger
Lorenz Hofmann
Rudy B. Horst
Julie & Rob Hutson
Theodore & Beverly Ifft
Lich Isaak
Sally Jandral
Paul & Andrea Jolly
Herbert A. Jolovitz
Lori Jones
Mary A. Juricek
Olgers Karlin
Elissa & Larry Kaufman
Warren Kaufman
Ruth Ann Kawko
Robert & Shirley Kelmoe
Victor Kesse
Edward Killham
Edward K Kimmel
Allison B Klein
Sheri Klug
Dale & Sheri Kluga
Robert & Mary Klunder
Ralph Koehring
Patti Kolster
Richard Kraut
Mark Kuehl
Maryann Laccabue
Jeffrey & Kimberly Laird
Carol L. Laxer
Lynnette Lenihan
Joseph A. Levin
Catherine Liesman
Runi Limary
Ronna Lindeken
Arne Lindström

Up to $49
Marcy Anderson
Morris M. Abrams
Dianne Abruzzo
Marcus Achenow
William Adams MD
Elliot J. Allentuck
Negar Amirkhah
Leonard J. Arzt
Willis Ashton
Joan Bailey
Cinde Baliton
Alice J. Ballard
Susana Bardin
Phillip C. Baridon
Leland C. Barrows
Frank Bash
William Behrens
Diane Benincasa
Alan Bennett
Morton Beroza
Melvin & Judy Berreth
Aaron Blanchard
Neal B. Bobys
Dennis & Karen Boren
Jodie Boulde
Cedar Boutil
Gail Tucker Boyar
Marlynn C. Bright
Louis Brisky
Jeffery D. Brockway
Thomas M. Brown CLU
John & Helen Burns
Robert Buzalits
Katie Campbell
Mary Cardoso
Michelle Carle
Anthony P. Cavallo Jr.
Amoz Chernoff
Axel & Karen Christiansen
Glenn Churchill
Louise Clouser
Joseph & Shirley Cohen
Samuel & Gertrude Cohen
Jan & Harry Cohen
Thomas & Karen Collins
Katherine Colwell
Dennis & Barb Andrews Cook
Paula K. Cooley
Stephen & Paula Cooley
Daniel Cooper
Melvin E. Cruser
Marissa Cunningham
Elizabeth Daly
William P. Davis
Victor Dawson C.D.
Peter & Jane Del Vejo
Dorothy Deriet
Stephanie & Tim Diekemper
Dorothy Dils
Ken & Sue Dombart
Leonard A. Donatelli
Daniel Droy
Thomas & Ruth Dwyer
Lindsey Eckhouse
Wayne Edwards
Lisa Erhardt
Daniel & Rachelle Eifert
William M. Eisenberg
Florence P. Elfant
George J. Ellis
Russell & Bonnie Emerson
Gabriel Etchevery
James & Carol Etherton
Lillian Falk
Elizabeth Falkenstein
Mary E. Falkenstein
John L. Farley
Gary & Liz Farmer
Harvey S. Fenster DDS
Jose Fernandez
Allan & Barbara Firestone
Barbara & Leo Fitzgerald
Roger-Guy Folly
Jerome Footer DDS
Pablo Forns-Samso
Joseph Forster
Linda Foster
Mary Jo Fox
Daniel & Mary Jo Fox
Jocelyn Francois
Mary Francois
Don & Joan Franklin
Esther M. Franklin
Joan Freedman
Elmer & Jean Freeze
Phillip J. Fulford
Bryan Gabaldon
Lorraine Garcia-Gordon
Patty Gardner
Robert Gaynes
Thomas & Marland Gengler
Pat George
Stanley Gibberman
Valerie Gilmore
Stephen & Nancy Glasser
Roger Goldberger
Rosalind Goldfarb Levitt PhD
Julie Goldman
Ann Goodman
Allocation of Funds for 2007
Total Expenditures $1,340,673.00

- Research Management $89,425
- Research Grant Awards $756,250
- Program Services $413,898
- Management and Fundraising $81,100

Allocation of Program Service Expenses

- LRG Research 34%
- Information & Education 15%
- Patient & Family Services 13%
- Advocacy 6%

Allocation of Research Grant Awards for 2007

- Brigham & Women’s Hospital- Harvard: Dr. Jonathan Fletcher 16%
- Catholic University of Leuven, Belgium: Dr. Maria Debiec-Rychter 17%
- The Cleveland Clinic: Dr. Brian Rubin 14%
- Memorial Sloan-Kettering Cancer Center: Dr. Cristina Antonescu, Dr. Peter Besmer 25%
- Oregon Health & Science University: Dr. Christopher Corless, Dr. Michael Heinrich 15%
- Stanford University Medical Center: Dr. Matthew van de Rijn 13%
The Life Raft Group (LRG) is an organization that provides support, information and assistance to patients and families with a rare cancer called Gastrointestinal Stromal Tumor (GIST). The LRG achieves this by providing an online community for patients and caregivers, supporting local in-person meetings, patient education through monthly newsletters and webcasts, one-on-one patient consultations, and most importantly, managing a major research project to find the cure for GIST.